CN110021437A - A kind of management method and system of diabetes - Google Patents
A kind of management method and system of diabetes Download PDFInfo
- Publication number
- CN110021437A CN110021437A CN201711047697.8A CN201711047697A CN110021437A CN 110021437 A CN110021437 A CN 110021437A CN 201711047697 A CN201711047697 A CN 201711047697A CN 110021437 A CN110021437 A CN 110021437A
- Authority
- CN
- China
- Prior art keywords
- inspection parameter
- user
- diabetes
- glucose
- assessment result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 68
- 238000007726 management method Methods 0.000 title claims abstract description 54
- 238000007689 inspection Methods 0.000 claims abstract description 118
- 230000000694 effects Effects 0.000 claims abstract description 40
- 238000012544 monitoring process Methods 0.000 claims abstract description 34
- 238000004393 prognosis Methods 0.000 claims abstract description 16
- 238000010835 comparative analysis Methods 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 67
- 239000008103 glucose Substances 0.000 claims description 59
- 238000011156 evaluation Methods 0.000 claims description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 32
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 21
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 21
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 21
- 235000005911 diet Nutrition 0.000 claims description 12
- 230000037213 diet Effects 0.000 claims description 12
- 230000002452 interceptive effect Effects 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 238000012502 risk assessment Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 5
- 125000005457 triglyceride group Chemical group 0.000 claims description 5
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 13
- 238000000034 method Methods 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000017667 Chronic Disease Diseases 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Biomedical Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
The invention discloses a kind of management method of diabetes and systems, are related to medical ancillary technique field.The management method, comprising: according to the operating mode that user selects, receive corresponding inspection parameter；The inspection parameter and preset standard comparative analysis are obtained into assessment result；The monitoring plan and Managed Solution of diabetes inspection parameter are provided according to the assessment result.The present invention carries out the assessment such as risk, curative effect, prognosis, and provide corresponding monitoring plan and daily management suggestion according to the inspection result of user's typing, provides specialized whole guidance and self-management.It can preferably realize the early stage intervention and treatment of screening and the early intervention prevention, guiding treatment scheme and disease of High-risk Group of Diabetes.
Description
Technical field
The present invention relates to medical ancillary technique field more particularly to the management methods and system of a kind of diabetes.
Background technique
Diabetes are a kind of metabolic diseases characterized by hyperglycemia, belong to chronic disease.Chronic diseases management refers to chronic
Non-communicable diseases and its risk factors carry out periodic detection, continuous to monitor, the medical behavior of assessment and pai n nursing management and
Process, main Connotation include slow sick early screening, slow disease risk profile, early warning and pai n nursing, and the synthesis of slow patient group
Management, chronic diseases management recruitment evaluation etc..In fact, chronic diseases management is the management to chronic patient and people at highest risk, including to it
Various management such as rational diet, behavioural habits, healthy psychology and intervention；Publicize correct chronic diseases management theory, knowledge, skill
Can, slow sick integrated control work etc. is carried out in a down-to-earth manner.
Current chronic diseases management is mainly carried out by medical and health organization, and the country of medical services prosperity passes through community service
Build chronic diseases management system, however it is domestic do not have such condition, patient or people at highest risk only lean on the hospital of finite number of time
It goes to a doctor to understand the state of an illness, tends not to find the problem in time.As portable inspection equipment gos deep into people's lives, led to by people
It crosses self-test grasp own situation and has become possibility, cooperate corresponding management system, more scientific chronic diseases management can be obtained and built
View.
Summary of the invention
It is an object of the invention to propose the management method and system of a kind of diabetes, inspection that can be daily according to user
As a result the slow sick monitoring plan and Managed Solution of individuation are provided, user is helped to carry out effective chronic diseases management.
To achieve this purpose, the present invention adopts the following technical scheme:
On the one hand, the present invention provides a kind of management method of diabetes, comprising:
According to the operating mode that user selects, corresponding inspection parameter is received；
The inspection parameter and preset standard comparative analysis are obtained into assessment result；
The monitoring plan and Managed Solution of diabetes inspection parameter are provided according to the assessment result.
Wherein, the operating mode selected according to user, receives corresponding inspection parameter, comprising:
If operating mode is risk assessment, inspection parameter is Triglyceride values in fasting blood sugar and blood, or is sugar
Triglyceride values in load 2h blood glucose value and blood；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
Judge threshold range belonging to the inspection parameter, obtains the risk class that user suffers from diabetes.
Wherein, the operating mode selected according to user, receives corresponding inspection parameter, comprising:
If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value and fasting blood sugar；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
The coefficient of variation of fasting blood-glucose in calculating cycle, judges the coefficient of variation of the inspection parameter and the fasting blood-glucose
Affiliated threshold range, or judge the variation feelings of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment
Condition obtains the curative effect grade of user's medication.
Further, if operating mode is curative effect evaluation, inspection parameter further includes Triglyceride values in blood；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
The coefficient of variation of fasting blood-glucose in calculating cycle, judges the coefficient of variation of the inspection parameter and the fasting blood-glucose
Affiliated threshold range, or judge the variation feelings of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment
Condition obtains the curative effect grade of user's medication.
Wherein, the operating mode selected according to user, receives corresponding inspection parameter, comprising:
If operating mode is prognosis evaluation, inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value；
Receive the presence or absence of user's input complication situation；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
Judge threshold range belonging to the inspection parameter, obtains the outcome grade of user；
Correspondingly, providing the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result, comprising:
According to the outcome grade and whether there is or not complication situations to provide the monitoring plan and pipe of diabetes inspection parameter
Reason scheme.
As a kind of perferred technical scheme, the monitoring plan of diabetes inspection parameter is being provided according to the assessment result
Before Managed Solution, further includes:
Obtain the essential information of user, including gender, age, height, weight, occupation, day activity level and diet feelings
Condition；
Correspondingly, providing the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result, comprising:
The calorie that user's consumption and intake are calculated according to the essential information, in conjunction with the assessment result and calculated result
The monitoring plan of diabetes inspection parameter and the Managed Solution of daily life are provided for user.
On the other hand, the present invention provides a kind of management system of diabetes, comprising:
User interactive module, the operating mode for being selected according to user, receives corresponding inspection parameter；
Evaluation module, for the inspection parameter and preset standard comparative analysis to be obtained assessment result；
It is recommended that output module, for providing monitoring plan and the manager of diabetes inspection parameter according to the assessment result
Case.
Wherein, the user interactive module is specifically used for:
If operating mode is risk assessment, inspection parameter is Triglyceride values in fasting blood sugar and blood, or is sugar
Triglyceride values in load 2h blood glucose value and blood；
Correspondingly, the evaluation module is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the risk class that user suffers from diabetes.
Wherein, the user interactive module is specifically used for:
If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value, in fasting blood sugar and blood
Triglyceride values；
Correspondingly, the evaluation module is specifically used for:
The coefficient of variation of fasting blood-glucose in calculating cycle, judges the coefficient of variation of the inspection parameter and the fasting blood-glucose
Affiliated threshold range, or judge the variation feelings of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment
Condition obtains the curative effect grade of user's medication.
Wherein, the user interactive module is specifically used for:
If operating mode is prognosis evaluation, inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value；It receives
The presence or absence of user's input complication situation；
Correspondingly, the evaluation module is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the outcome grade of user；
Correspondingly, the suggestion output module is specifically used for:
According to the outcome grade and whether there is or not complication situations to provide the monitoring plan and pipe of diabetes inspection parameter
Reason scheme.
Further, the management system further include: essential information obtains module, for mentioning according to the assessment result
Before the monitoring plan and Managed Solution of diabetes inspection parameter,
Obtain the essential information of user, including gender, age, height, weight, occupation, day activity level and diet feelings
Condition；
Correspondingly, the suggestion output module is specifically used for:
The calorie that user's consumption and intake are calculated according to the essential information, in conjunction with the assessment result and calculated result
The monitoring plan of diabetes inspection parameter and the Managed Solution of daily life are provided for user.
The invention has the benefit that
According to the inspection result of user's typing, the assessment such as risk, curative effect, prognosis is carried out, and provides corresponding monitoring
Plan and daily management suggestion provide specialized whole guidance and self-management.It can preferably realize the high-risk people of diabetes
The early stage intervention and treatment of the screening of group and early intervention prevention, guiding treatment scheme and disease.
Detailed description of the invention
Fig. 1 is the flow chart of the management method for the diabetes that the embodiment of the present invention one provides；
Fig. 2 is the structural schematic diagram of the management system of diabetes provided by Embodiment 2 of the present invention.
Specific embodiment
To keep the technical problems solved, the adopted technical scheme and the technical effect achieved by the invention clearer, below
It will the technical scheme of the embodiment of the invention will be described in further detail in conjunction with attached drawing, it is clear that described embodiment is only
It is a part of the embodiment of the present invention, instead of all the embodiments.
Embodiment one
The present embodiment provides a kind of management methods of diabetes, carry out disease suitable for diabetic and people at highest risk
Track of the whole process and management, are suitable for plurality of application scenes.This method is executed by a kind of management system of diabetes, the system by
Software and/or hardware composition is generally integrated in intelligent terminal or examines inside equipment, have the integrated feature of product, collects number
According to detection, acquisition, transmission, analyze, be stored in one, specialized pipe can be provided for diabetic and people at highest risk
Reason, personalized guidance.
Fig. 1 is the flow chart of the management method for the diabetes that the embodiment of the present invention one provides.As shown in Figure 1, the manager
Method includes the following steps:
S11 receives corresponding inspection parameter according to the operating mode that user selects.
Operating mode includes risk assessment, curative effect evaluation and prognosis evaluation.
If operating mode is risk assessment, inspection parameter includes both fasting blood sugar and glucose load 2h blood glucose value or two
Person is first, further include Triglyceride values in blood；If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value
And fasting blood sugar, as a kind of preferred embodiment, inspection parameter further includes Triglyceride values in blood；If operating mode
For prognosis evaluation, then inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value, and independently selects to fill in by user
Whether there is or not complication situations.
Above-mentioned inspection parameter can be tested by the pertinent instruments of hospital, can also pass through portable equipment self-test with user.
Survey report can be manually entered by user, can also be imported by data line interface or network interface imports.
The inspection parameter and preset standard comparative analysis are obtained assessment result by S12.
If operating mode is risk assessment, threshold range belonging to corresponding inspection parameter is judged, obtain user and suffer from sugar
Urinate the risk class of disease.The level of Triglyceride values is different in fasting blood sugar, glucose load 2h blood glucose value and blood, represents user's
Risk is also different, risk class include minuent, moderate, height and it is high, it can be achieved that High-risk Group of Diabetes screening.
The threshold range of inspection parameter and the corresponding relationship of risk class is exemplified below.Fasting blood sugar <
In 5.0mmol/L and blood when Triglyceride values < 2.3mmol/L, it can determine that as low risk；Fasting blood sugar is between 5.6-
Between 6.1mmol/L and in blood when Triglyceride values < 2.3mmol/L, it can determine that as moderate risk；Fasting blood sugar is between 6.1-
Between 7.0mmol/L and in blood when Triglyceride values < 2.3mmol/L, it can determine that as high risk；Fasting blood sugar is between 6.1-
Between 7.0mmol/L and in blood when Triglyceride values >=2.3mmol/L, it can determine that as high risk.
If operating mode is curative effect evaluation, the fasting blood-glucose data recorded in measurement period calculate the change of fasting blood-glucose
Different coefficient, and the threshold range in conjunction with described in other inspection parameters is judged, the curative effect etc. that user executes therapeutic scheme is obtained
Grade.If the inspection data of only cycle therapy, the inspection data are judged in which threshold range, before having treatment
The inspection data of two groups of comparisons afterwards then judge to check threshold range belonging to the variable quantity of data.Curative effect grade includes that curative effect is aobvious
It writes, curative effect is obvious, curative effect is general, without positive effect and weak curative effect.
Firstly, judging the light and heavy degree of the state of an illness according to the inspection data of record, comprising: the state of an illness is relatively light, the state of an illness is general and disease
Feelings are serious.Wherein the state of an illness is compared with gently referring to: diabetes newly diagnose that the course of disease is short or < 65 years old young without complication and disease accompanied without hypoglycemic
The patient of pharmaceutical intervention person or glucose-lowering treatment without the side effects such as hypoglycemia and weight gain.The state of an illness refers generally to: most of non-pregnant
Adult patient, < 65 years old oral hypoglycemic drug cannot be up to standard and share or use instead insulin therapy；>=65 years old dirty without risk of hypoglycemia
Device well expected life cycle is greater than 15 years patients.Be in a bad way finger: diabetic duration is longer, there is severe hypoglycemia history, pre-
Phase restricted lifetime has advanced stage capilary or macroangiopathic complication, has and see more concomitant diseases, and patient up to standard is difficult to after treatment.Disease
The light and heavy degree of feelings is different, and applicable threshold range is also different.
The threshold range of inspection parameter and the corresponding relationship of curative effect grade is exemplified below.If user's state of an illness gentlier only has
One section of cycle therapy checks data, glycosylated hemoglobin value < 6.5% and fasting blood-glucose coefficient of variation CV value < 0.29, then can sentence
It is significant in efficacy for breaking.If user's state of an illness gentlier has the inspection data of pretherapy and post-treatment two groups of comparisons, glycosylated hemoglobin value after treatment <
Fasting blood-glucose coefficient of variation CV value is greater than before 6.5% (or glycosylated hemoglobin value rate of descent >=30% before and after treatment) and treatment
Fasting blood-glucose coefficient of variation CV value after treatment then can determine whether to be significant in efficacy.
If operating mode is prognosis evaluation, according to whether there is or not complication to judge threshold value belonging to corresponding inspection parameter respectively
Range obtains the outcome grade of user.Outcome grade includes preferable, general, poor and poor.
The threshold range of inspection parameter and the corresponding relationship of outcome grade is exemplified below.Glycosylated hemoglobin value
< 7% and total cholesterol value between 3.0-5.2mmol/L when, illustrate that outcome is preferable；Glycosylated hemoglobin value < 7% and
When total cholesterol value > 5.2mmol/L, illustrate that outcome is general；Glycosylated hemoglobin value 7-8% and total cholesterol value >
When 5.2mmol/L, illustrate that outcome is poor；Glycosylated hemoglobin value > 8% and when total cholesterol > 5.2mmol/L, illustrates pre-
Effect is poor afterwards；When without complication, the occurrence and development that prognosis scheme instructs user to prevent complication are adjusted as the case may be.
S13 provides the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result.
When risk assessment, for different risk class, it will provide the user with different managerial integrations.Low and moderate
Risk then asks user to keep good living habit, pays attention to adjustment of diet, reinforces taking exercise；Height and high risk are then pointed out
Abnormal index, it is proposed that the timely simultaneously periodic review of user reinforces the therapeutic intervention of life style, and provide reasonable diet and work
Breath planning is for reference, if intervention effect is bad, it is proposed that sees a doctor in time, pharmaceutical intervention treatment may be selected.
Diabetes be due to insulin deficit and (or) insulin resistance caused by one group with long term hyperglycemia be main
The metabolic syndrome of feature, its most important key foundation of High-risk Group of Diabetes is Glucose metabolic abnormality and abnormal energy metabolism.
When insulin deficit and (or) insulin are resisted, glucose cannot be efficiently entering in histocyte, the utilization of glucose
Rate reduces, and blood glucose level is caused to increase.And the decomposition of glucose utilizes reduction, and can further result in energy and generate reduction, when
When energy supply deficiency, human body then needs fat supplement energy supply to be called, to lead by corresponding energy metabolism regulation mechanism
The concentration of fatty acid is caused to increase, and wherein triglycerides is that most important energy resource supply and stored substance also therefore lead to blood
In triglyceride levels increase.When " double height " state occur in blood glucose, triglyceride levels, show glycometabolism occurred
And the exception of energetic supersession, illustrate that the risk of diabetes is high；And when wherein only have single index raising when, often vulnerable to
The influence of other factors, such as: when only blood glucose level increases, it may be possible to be influenced by mood, diet etc. and lead to blood glucose level
Temporary raising；When only triglyceride levels increase, it may be possible to because undesirable living habit or hyperlipemia etc. are drawn
It rises.Therefore, only blood glucose level is assessed in the prior art to the risk of diabetes, accuracy is inadequate.The present embodiment is logical
It crosses 2 hours blood glucose value combination Triglyceride values of fasting blood-glucose or glucose load to be assessed, judges that it whether there is " double height " state,
The influence that other disturbing factors can effectively be excluded makes more accurate assessment to risk degree.To carry out early stage intervention,
The lifestyle modification etc. that science is carried out to people at highest risk, effectively can prevent or delay the generation of diabetes.
When curative effect evaluation, if effective or effective, it is proposed that user takes medicine according to original plan, and keeps good life and drink
Dietary habits；If invalid, then suggest user's further consultation, medication is adjusted according to the suggestion of doctor.
The blood glucose average level that it is 2-3 months in the period that glycosylated hemoglobin value, which reflects, cannot directly reflect blood glucose fluctuation
Situation.And multiple studies have shown that, blood glucose fluctuation can excite different metabolic pathways to lead to capilary and macroangiopathy.Fasting blood
The sugared coefficient of variation (FPG-CV) is the ratio of standard deviation and mean, can eliminate what average level difference compared degree of variation
It influences, reflects the fluctuation situation of blood glucose in the daytime.It, can be more comprehensively by comprehensively considering blood glucose fluctuation and HbA1c these two aspects information
Understand the control situation of blood glucose.The raising of blood glucose level, it is meant that the utilization rate of glucose reduces, and cell tissue energy supply is insufficient,
Human body needs that fat is called to provide energy, increases to will lead to triglyceride levels in blood.Therefore, pass through triglycerides in blood
Value can reflect the case where lipid metaboli and energetic supersession.By triplicity, can judge while judging whether glycometabolism is normal
Whether with lipid metaboli and the exception of energetic supersession.So as to the therapeutic effect to diabetes do one deeper into, it is comprehensive
Evaluation, is more conducive to adjuvant clinical decision, direction of medication usage.
When prognosis evaluation, according to outcome grade and whether there is or not complication situations to provide the monitoring meter of diabetes inspection parameter
Draw and Managed Solution.Outcome grade is preferably or general, it is proposed that user controls the state of an illness, regular further consultation, note according to original plan
Meaning diet etc.；If outcome grade be it is poor or poor, have complication, instruct user medical according to corresponding complication or change
Become prognosis scheme；It is uncomplicated, prognosis scheme is adjusted as the case may be, and user is instructed to prevent the generation of complication, development.
For diabetic, the control situation of blood glucose is to determine the core of its prognosis.Optimize glycemic control, Ke Yicong
It fundamentally reduces complication risk or complication is delayed to be in progress.And it is chronically at carbohydrate metabolism disturbance, it will lead to chronic high blood
Sugared state causes chronic inflammation, endothelial cell damage, hypercoagulative state and microcirculation disorder etc., leads to various tissues, organ dysfunction
Obstacle.The pathologic basis of diabetic complication, is all the blood vessel scleratheroma lesion of corresponding organ, and kidney, eye, pedopathy are with small
Based on blood vessel, brain, heart disease are based on medium vessels, but its pathologic basis is all atherosclerosis, and lead to artery sclerosis
Immediate cause the number of blood lipid be.Glycosylated hemoglobin is the golden index for evaluating glycemic control situation, and total cholesterol, then
It is the index for reflecting vascular lesion state, the two combines, then can the occurrence and development of diabetic duration and complication be done with a standard
True prediction and judgement, it helps the early detection or treatment of diabetic complication.
Further, before monitoring plan and Managed Solution that blood glucose is provided according to the assessment result, further includes: obtain
The essential information of user, including gender, age, height, weight, occupation, day activity level and diet situation；Correspondingly, root
According to the assessment result and the essential information, monitoring plan and the management of more reasonable diabetes inspection parameter are customized for user
Scheme.
Specifically, it is daily to calculate user according to the gender of user, age, height, weight, occupation and day activity level
The intake of required calorie, whole by diet and movement etc. instruct, and carry out the lifestyle modification of science.According to
Interim assessment result, makes corresponding adjustment, and monitoring and the Managed Solution of individuation are formulated for user.
The beneficial effect of the present embodiment is: 1) independent of doctor, big data, realizing the judgement more refined；2)
A variety of specific combinations are carried out by multiple diabetes core index parameters, so that assessment result is more comprehensively, accurately；3) collection risk is commented
Estimate, curative effect evaluation, prognosis evaluation are in one, different crowd can targetedly be managed；4) inspection of diabetes correlation can be achieved
Look into data record, storage and the analysis of parameter；5) it is provided during daily self-management for diabetic more professional
Guiding opinion and management.
Embodiment two
The present invention provides a kind of management system of diabetes, to execute the management method of above-described embodiment, solves identical
The technical issues of, reach identical technical effect.The management system is generally integrated in intelligent terminal or examines inside equipment.
Fig. 2 is the structural schematic diagram of the management system of diabetes provided by Embodiment 2 of the present invention.As shown in Fig. 2, the pipe
Reason system includes:
User interactive module 21, the operating mode for being selected according to user, receives corresponding inspection parameter.
Evaluation module 22, for the inspection parameter and preset standard comparative analysis to be obtained assessment result.
It is recommended that output module 23, for providing monitoring plan and the management of diabetes inspection parameter according to the assessment result
Scheme.
First, the user interactive module 21 is specifically used for:
If operating mode is risk assessment, inspection parameter is Triglyceride values in fasting blood sugar and blood, or is sugar
Triglyceride values in load 2h blood glucose value and blood；
Correspondingly, the evaluation module 22 is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the risk class that user suffers from diabetes.
Second, the user interactive module 21 is specifically used for:
If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value, in fasting blood sugar and blood
Triglyceride values；
Correspondingly, the evaluation module 22 is specifically used for:
The coefficient of variation of fasting blood-glucose in calculating cycle, judges the coefficient of variation of the inspection parameter and the fasting blood-glucose
Affiliated threshold range, or judge the variation feelings of the coefficient of variation of inspection parameter described in two adjacent groups and the fasting blood-glucose
Condition obtains the curative effect grade that user executes therapeutic scheme.
Third, the user interactive module 21 is specifically used for:
If operating mode is prognosis evaluation, inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value；It receives
The presence or absence of user's input complication situation.
Correspondingly, the evaluation module 22 is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the outcome grade of user.
Correspondingly, the suggestion output module 23 is specifically used for:
According to the outcome grade and whether there is or not complication situations to provide the monitoring plan and pipe of diabetes inspection parameter
Reason scheme.
Further, the management system further include: essential information obtains module 24, for according to the assessment result
Before monitoring plan and Managed Solution that diabetes inspection parameter is provided,
Obtain the essential information of user, including gender, age, height, weight, occupation, day activity level and diet feelings
Condition；
Correspondingly, the suggestion output module 23 is specifically used for:
The calorie that user's consumption and intake are calculated according to the essential information, in conjunction with the assessment result and calculated result
The monitoring plan of diabetes inspection parameter and the Managed Solution of daily life are provided for user.
Management system provided in this embodiment is it is intended that user provides current check plan and disease control suggestion, for user
It reduces risk or instructs its partner treatment, pay close attention to outcome, help user's self-monitoring and management of disease, use
The disease control at family is more planned.
The technical principle of the invention is described above in combination with a specific embodiment.These descriptions are intended merely to explain of the invention
Principle, and shall not be construed in any way as a limitation of the scope of protection of the invention.Based on the explanation herein, the technology of this field
Personnel can associate with other specific embodiments of the invention without creative labor, these modes are fallen within
Within protection scope of the present invention.
Claims (11)
1. a kind of management method of diabetes, it is characterised in that:
According to the operating mode that user selects, corresponding inspection parameter is received；
The inspection parameter and preset standard comparative analysis are obtained into assessment result；
The monitoring plan and Managed Solution of diabetes inspection parameter are provided according to the assessment result.
2. management method according to claim 1, which is characterized in that according to the operating mode that user selects, receive corresponding
Inspection parameter, comprising:
If operating mode is risk assessment, inspection parameter is Triglyceride values in fasting blood sugar and blood, or is glucose load
Triglyceride values in 2h blood glucose value and blood；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
Judge threshold range belonging to the inspection parameter, obtains the risk class that user suffers from diabetes.
3. management method according to claim 1, which is characterized in that according to the operating mode that user selects, receive corresponding
Inspection parameter, comprising:
If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value and fasting blood sugar；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
The coefficient of variation of fasting blood-glucose in calculating cycle, belonging to the coefficient of variation for judging the inspection parameter and the fasting blood-glucose
Threshold range, or judge the situation of change of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment, obtain
Obtain the curative effect grade that user executes therapeutic scheme.
4. management method according to claim 3, which is characterized in that if operating mode is curative effect evaluation, inspection parameter
It further include Triglyceride values in blood；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
The coefficient of variation of fasting blood-glucose in calculating cycle, belonging to the coefficient of variation for judging the inspection parameter and the fasting blood-glucose
Threshold range, or judge the situation of change of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment, obtain
Obtain the curative effect grade that user executes therapeutic scheme.
5. management method according to claim 1, which is characterized in that according to the operating mode that user selects, receive corresponding
Inspection parameter, comprising:
If operating mode is prognosis evaluation, inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value；
Receive the presence or absence of user's input complication situation；
Correspondingly, the inspection parameter and preset standard comparative analysis are obtained assessment result, comprising:
Judge threshold range belonging to the inspection parameter, obtains the outcome grade of user；
Correspondingly, providing the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result, comprising:
According to the outcome grade and whether there is or not complication situations to provide monitoring plan and the manager of diabetes inspection parameter
Case.
6. management method according to claim 1, which is characterized in that providing diabetes inspection according to the assessment result
Before the monitoring plan and Managed Solution of parameter, further includes:
Obtain the essential information of user, including gender, age, height, weight, occupation, day activity level and diet situation；
Correspondingly, providing the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result, comprising:
The intake of calorie needed for calculating user daily according to the essential information, in conjunction with the assessment result and calculated result
The monitoring plan of diabetes inspection parameter and the Managed Solution of daily life are provided for user.
7. a kind of management system of diabetes characterized by comprising
User interactive module, the operating mode for being selected according to user, receives corresponding inspection parameter；
Evaluation module, for the inspection parameter and preset standard comparative analysis to be obtained assessment result；
It is recommended that output module, for providing the monitoring plan and Managed Solution of diabetes inspection parameter according to the assessment result.
8. management system according to claim 7, which is characterized in that the user interactive module is specifically used for:
If operating mode is risk assessment, inspection parameter is Triglyceride values in fasting blood sugar and blood, or is glucose load
Triglyceride values in 2h blood glucose value and blood；
Correspondingly, the evaluation module is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the risk class that user suffers from diabetes.
9. management system according to claim 7, which is characterized in that the user interactive module is specifically used for:
If operating mode is curative effect evaluation, inspection parameter includes glycosylated hemoglobin value, glycerol in fasting blood sugar and blood
Three ester values；
Correspondingly, the evaluation module is specifically used for:
The coefficient of variation of fasting blood-glucose in calculating cycle, belonging to the coefficient of variation for judging the inspection parameter and the fasting blood-glucose
Threshold range, or judge the situation of change of the coefficient of variation of the inspection parameter and the fasting blood-glucose before and after treatment, obtain
Obtain the curative effect grade that user executes therapeutic scheme.
10. management system according to claim 7, which is characterized in that the user interactive module is specifically used for:
If operating mode is prognosis evaluation, inspection parameter includes glycosylated hemoglobin value and/or total cholesterol value；Receive user
The presence or absence of input complication situation；
Correspondingly, the evaluation module is specifically used for:
Judge threshold range belonging to the inspection parameter, obtains the outcome grade of user；
Correspondingly, the suggestion output module is specifically used for:
According to the outcome grade and whether there is or not complication situations to provide monitoring plan and the manager of diabetes inspection parameter
Case.
11. management system according to claim 7, which is characterized in that further include: essential information obtains module, is used for
Before monitoring plan and Managed Solution that diabetes inspection parameter is provided according to the assessment result,
Obtain the essential information of user, including gender, age, height, weight, occupation, day activity level and diet situation；
Correspondingly, the suggestion output module is specifically used for:
The calorie that user's consumption and intake are calculated according to the essential information is to use in conjunction with the assessment result and calculated result
Family provides the monitoring plan of diabetes inspection parameter and the Managed Solution of daily life.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047697.8A CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711047697.8A CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110021437A true CN110021437A (en) | 2019-07-16 |
| CN110021437B CN110021437B (en) | 2024-04-26 |
Family
ID=67186720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711047697.8A Active CN110021437B (en) | 2017-10-31 | 2017-10-31 | Diabetes management method and system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110021437B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111599473A (en) * | 2020-05-21 | 2020-08-28 | 北京因普乐健康科技有限公司 | Blood glucose related index information processing method and device and electronic equipment |
| CN111710411A (en) * | 2020-05-29 | 2020-09-25 | 中润普达(十堰)大数据中心有限公司 | Intelligent disease presumption system based on blood fat inspection indexes |
| CN111968748A (en) * | 2020-08-21 | 2020-11-20 | 南通大学 | Modeling method of diabetic complication prediction model |
| CN112735588A (en) * | 2021-01-12 | 2021-04-30 | 芜湖云枫信息技术有限公司 | Hierarchical combined management system and method for diabetes and diabetic nephropathy |
| CN116230238A (en) * | 2023-05-08 | 2023-06-06 | 寿光市人民医院 | Monitoring and early warning system for cardiovascular disease |
| CN117711571A (en) * | 2024-02-06 | 2024-03-15 | 首都医科大学宣武医院 | Blood sugar management and detection system for gestational diabetes patients |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030074340A1 (en) * | 2001-09-26 | 2003-04-17 | Klaus Abraham-Fuchs | System for checking treatment plans |
| WO2006011869A2 (en) * | 2004-06-28 | 2006-02-02 | Paul M Rosman | Predictive trement of dysglycemic excursions associated with diabetes mellitus |
| US20070167395A1 (en) * | 2006-01-17 | 2007-07-19 | Isaac Eliaz | Compositions and methods for treating diabetes |
| US20100160768A1 (en) * | 2008-12-24 | 2010-06-24 | Marrouche Nassir F | Therapeutic outcome assessment for atrial fibrillation |
| US20100249531A1 (en) * | 2009-03-19 | 2010-09-30 | Hanlon Alaina B | Medical health information system |
| CN102999686A (en) * | 2011-09-19 | 2013-03-27 | 上海煜策信息科技有限公司 | Health management system and implementation method thereof |
| US20130102867A1 (en) * | 2010-12-29 | 2013-04-25 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
| CN103250158A (en) * | 2010-10-15 | 2013-08-14 | 霍夫曼-拉罗奇有限公司 | Medical devices that support enhanced system extensibility for diabetes care |
| WO2014169268A1 (en) * | 2013-04-12 | 2014-10-16 | Biophysical Corporation, Inc. | System and method for identifying patients most likely to subscribe to a prevention program for type-2 diabetes |
| US20150018633A1 (en) * | 2011-06-23 | 2015-01-15 | University Of Virginia Patent Foundation | Unified Platform for Monitoring and Control of Blood Glucose Levels in Diabetic Patients |
| CN104657621A (en) * | 2015-03-09 | 2015-05-27 | 上海万达全程健康门诊部有限公司 | System and method for evaluating body health states based on multi-point collection |
| CN105160199A (en) * | 2015-09-30 | 2015-12-16 | 刘毅 | Continuous blood sugar monitoring based method for processing and displaying diabetes management information with intervention information |
| CN204946110U (en) * | 2015-07-06 | 2016-01-06 | 青岛大学附属医院 | A kind of diabetes electronic records management control system |
| CN105574337A (en) * | 2015-12-16 | 2016-05-11 | 上海亿保健康管理有限公司 | Health evaluation device |
| CN106108857A (en) * | 2016-08-23 | 2016-11-16 | 王伏声 | Diabetic foot classification of severity evaluates system |
| US20160342764A1 (en) * | 2015-05-19 | 2016-11-24 | Universidad De Vigo | System, computer-implemented method and computer program product for individualized multiple-disease quantitative risk assessment |
| CN106326654A (en) * | 2016-08-24 | 2017-01-11 | 北京辛诺创新科技有限公司 | Big data cloud analysis-based health prediction system, intelligent terminal and server |
| CN106979982A (en) * | 2016-01-19 | 2017-07-25 | 上海市第六人民医院 | It is a kind of to be predicted for diabetes risk, treat the method evaluated and kit |
| CN107016243A (en) * | 2017-04-06 | 2017-08-04 | 浙江大学 | Diabetes risk appraisal procedure |
| CN107292115A (en) * | 2017-07-12 | 2017-10-24 | 冯培根 | Artificial intelligence fititious doctor diagnosis and therapy system and method based on diabetes |
-
2017
- 2017-10-31 CN CN201711047697.8A patent/CN110021437B/en active Active
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030074340A1 (en) * | 2001-09-26 | 2003-04-17 | Klaus Abraham-Fuchs | System for checking treatment plans |
| WO2006011869A2 (en) * | 2004-06-28 | 2006-02-02 | Paul M Rosman | Predictive trement of dysglycemic excursions associated with diabetes mellitus |
| US20070167395A1 (en) * | 2006-01-17 | 2007-07-19 | Isaac Eliaz | Compositions and methods for treating diabetes |
| US20100160768A1 (en) * | 2008-12-24 | 2010-06-24 | Marrouche Nassir F | Therapeutic outcome assessment for atrial fibrillation |
| US20100249531A1 (en) * | 2009-03-19 | 2010-09-30 | Hanlon Alaina B | Medical health information system |
| CN103250158A (en) * | 2010-10-15 | 2013-08-14 | 霍夫曼-拉罗奇有限公司 | Medical devices that support enhanced system extensibility for diabetes care |
| US20130102867A1 (en) * | 2010-12-29 | 2013-04-25 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
| US20150018633A1 (en) * | 2011-06-23 | 2015-01-15 | University Of Virginia Patent Foundation | Unified Platform for Monitoring and Control of Blood Glucose Levels in Diabetic Patients |
| CN102999686A (en) * | 2011-09-19 | 2013-03-27 | 上海煜策信息科技有限公司 | Health management system and implementation method thereof |
| WO2014169268A1 (en) * | 2013-04-12 | 2014-10-16 | Biophysical Corporation, Inc. | System and method for identifying patients most likely to subscribe to a prevention program for type-2 diabetes |
| CN104657621A (en) * | 2015-03-09 | 2015-05-27 | 上海万达全程健康门诊部有限公司 | System and method for evaluating body health states based on multi-point collection |
| US20160342764A1 (en) * | 2015-05-19 | 2016-11-24 | Universidad De Vigo | System, computer-implemented method and computer program product for individualized multiple-disease quantitative risk assessment |
| CN204946110U (en) * | 2015-07-06 | 2016-01-06 | 青岛大学附属医院 | A kind of diabetes electronic records management control system |
| CN105160199A (en) * | 2015-09-30 | 2015-12-16 | 刘毅 | Continuous blood sugar monitoring based method for processing and displaying diabetes management information with intervention information |
| CN105574337A (en) * | 2015-12-16 | 2016-05-11 | 上海亿保健康管理有限公司 | Health evaluation device |
| CN106979982A (en) * | 2016-01-19 | 2017-07-25 | 上海市第六人民医院 | It is a kind of to be predicted for diabetes risk, treat the method evaluated and kit |
| CN106108857A (en) * | 2016-08-23 | 2016-11-16 | 王伏声 | Diabetic foot classification of severity evaluates system |
| CN106326654A (en) * | 2016-08-24 | 2017-01-11 | 北京辛诺创新科技有限公司 | Big data cloud analysis-based health prediction system, intelligent terminal and server |
| CN107016243A (en) * | 2017-04-06 | 2017-08-04 | 浙江大学 | Diabetes risk appraisal procedure |
| CN107292115A (en) * | 2017-07-12 | 2017-10-24 | 冯培根 | Artificial intelligence fititious doctor diagnosis and therapy system and method based on diabetes |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111599473A (en) * | 2020-05-21 | 2020-08-28 | 北京因普乐健康科技有限公司 | Blood glucose related index information processing method and device and electronic equipment |
| CN111710411A (en) * | 2020-05-29 | 2020-09-25 | 中润普达(十堰)大数据中心有限公司 | Intelligent disease presumption system based on blood fat inspection indexes |
| CN111968748A (en) * | 2020-08-21 | 2020-11-20 | 南通大学 | Modeling method of diabetic complication prediction model |
| CN112735588A (en) * | 2021-01-12 | 2021-04-30 | 芜湖云枫信息技术有限公司 | Hierarchical combined management system and method for diabetes and diabetic nephropathy |
| CN116230238A (en) * | 2023-05-08 | 2023-06-06 | 寿光市人民医院 | Monitoring and early warning system for cardiovascular disease |
| CN116230238B (en) * | 2023-05-08 | 2023-07-21 | 寿光市人民医院 | Monitoring and early warning system for cardiovascular disease |
| CN117711571A (en) * | 2024-02-06 | 2024-03-15 | 首都医科大学宣武医院 | Blood sugar management and detection system for gestational diabetes patients |
| CN117711571B (en) * | 2024-02-06 | 2024-05-14 | 首都医科大学宣武医院 | Blood sugar management and detection system for gestational diabetes patients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110021437B (en) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110021437A (en) | A kind of management method and system of diabetes | |
| Boneva et al. | Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population-based study | |
| US20210169409A1 (en) | Systems of centralized data exchange for monitoring and control of blood glucose | |
| US20200214629A1 (en) | Unified platform for monitoring and control of blood glucose levels in diabetic patients | |
| KR100776070B1 (en) | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data | |
| US7395158B2 (en) | Method of screening for disorders of glucose metabolism | |
| Kanaya et al. | Prevalence and correlates of diabetes in South Asian Indians in the United States: findings from the metabolic syndrome and atherosclerosis in South Asians living in America study and the multi-ethnic study of atherosclerosis | |
| EP2596448B1 (en) | System and method considering the effect of physical activity on the glucoregulatory system | |
| Agarwal et al. | Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease | |
| US6923763B1 (en) | Method and apparatus for predicting the risk of hypoglycemia | |
| US9519755B2 (en) | Method and system for evaluating a physiological state depicting a person's resources | |
| US20150150516A1 (en) | Biological information processing system, wearable device, server system, method for controlling biological information processing system, and information storage medium | |
| US20080294021A1 (en) | System and Method for the Management or Control of Cardiovascular Related Diseases, Such as Hypertension | |
| Goetsch et al. | The effects of stress, mood, and coping on blood glucose in NIDDM: A prospective pilot evaluation | |
| US20020132279A1 (en) | Formula to manipulate blood glucose via the calculated ingestion of carbohydrate | |
| US20150073754A1 (en) | Method and system for calculating indices for diabetes control | |
| CN112309570A (en) | Personalized benchmarking, visualization and handover | |
| Beckham et al. | Ambulatory cardiovascular activity and hostility ratings in women with chronic posttraumatic stress disorder | |
| CN114400095A (en) | Individual health state-based family doctor differential signing service system | |
| Miyamoto et al. | The correlation between CVR-R and carotid atherosclerosis in type 2 diabetes mellitus patients with diabetic neuropathy | |
| Ashisha et al. | Comorbidies of Blood Pressure and Blood Glucose: Challenges and Future Trends | |
| Liu | Analysis of the Effect of Continuous Nursing Practice on Case Management of Intensive-Stage Diabetes Patients | |
| Hsu | Application of Perturbation Theory on Risk Assessments in Predicting Coronary Vascular Disease, Chronic Kidney Disease, and Diabetic Retinopathy using a Perturbation Factor of Combined Metabolism Index & Glucose Fluctu-ation over a Period of 11.5 years based on GH-Method: Math-Physical Medicine (No. 481) | |
| CN117198509A (en) | Cardiovascular disease risk period assessment method based on big data | |
| Spannella et al. | CHANGES IN BLOOD PRESSURE AND METABOLIC PARAMETERS IN OVERWEIGHT PATIENTS WITH OBSTRUCTIVE SLEEP APNOEA SYNDROME AFTER 3-MONTH CONTINUOUS POSITIVE AIRWAY PRESSURE THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |